01:27 PM EDT, 10/06/2025 (MT Newswires) -- Skye Bioscience ( SKYE ) shares plummeted 60% amid heavy trading intraday after the company said Monday its phase 2a trial of nimacimab to treat patients with obesity missed its primary endpoint of weight loss compared with placebo.

More than 11.8 million shares traded intraday compared with a daily average of about 386,000.

Dragonfly Energy ( DFLI ) said Monday it priced an underwritten offering of 20 million shares at $1.25 each for gross proceeds of $25 million and said it plans to use the net proceeds for working capital and other general corporate purposes.

Shares slumped 28% as intraday trading volume soared to over 70.8 million from a daily average of about 41.5 million.

JPMorgan downgraded shares of Abercrombie & Fitch ( ANF ) to neutral from overweight while cutting its price target to $103 from $145.

Shares of Abercrombie traded 7.2% lower as intraday trading volume rose to more than 2.57 million from a daily average of roughly 1.94 million.

Price: 1.88, Change: -2.87, Percent Change: -60.42